BioTuesdays

Category - Markets

ViewRay Logo
Markets

BTIG cuts ViewRay to neutral and removes PT

BTIG downgraded ViewRay (NASDAQ:VRAY) to “neutral” from “buy” and removed its price target after the company’s 2020 revenue guidance of $58-million to $95-million was “well below even the lowest Street estimates.” The...

March 13, 2020
Castle Biosciences
Markets

BTIG ups Castle Biosciences PT to $41 from $32

BTIG raised its price target for Castle Biosciences (NASDAQ:CSTL) to $41 from $32 after the company reported fourth quarter results and initial revenue guidance for 2020. The stock closed at $29.36 on March 10. Castle...

March 11, 2020
Tracon Pharmaceuticals Logo
Markets

HCW halves Tracon Pharma PT to $6 from $13

H.C. Wainwright slashed its price target for Tracon Pharmaceuticals (NASDAQ:TCON) to $6 from $13, but reiterated its “buy” rating, after the company and partner, Santen Pharmaceutical, discontinued development of DE-122...

March 10, 2020
electroCore Logo
Markets

HCW starts electroCore at buy; PT $2

H.C. Wainwright initiated coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and $2 price target. The stock closed at 65 cents on March 9. electroCore is commercializing its lead product, gammaCore, the only FDA...

March 10, 2020
Corvus Pharmaceuticals
Markets

HCW starts Corvus Pharma at buy; PT $10

H.C. Wainwright launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with a “buy” rating and $10 price target. The stock closed at $2.72 on March 9. Corvus is focused on developing precision medicines to treat...

March 10, 2020
Eloxx Pharma
Markets

HCW slashes Eloxx Pharma PT to $3 from $10

H.C. Wainwright slashed its price target for Eloxx Pharmaceuticals (NASDAQ:ELOX) to $3 from $10 and retained its “neutral” rating, saying the strength of the company’s ELX-02 program in cystic fibrosis is yet to be...

March 6, 2020
Osmotica Pharmaceuticals
Markets

SVB Leerink starts Osmotica Pharma at OP; PT $10

SVB Leerink launched coverage of Osmotica Pharmaceuticals (NASDAQ:OSMT) with an “outperform rating” and $10 price target. The stock closed at $5.47 on March 5. Analyst Ami Fadia writes that her rating is based on the...

March 6, 2020
Precision Biosciences
Markets

Stifel starts Precision Biosciences at buy; PT $21

Stifel initiated coverage of Precision Biosciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $8.11 on March 4. “Our positive thesis is predicated on optimism that Precision’s allogeneic...

March 5, 2020